The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Collaborates with VisionSpring to conduct eye check-up camps for underprivileged children
YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
This strategic partnership will also enable KIMS to exercise call option (not an obligation) to acquire majority stake in UAIMS Hospital in the coming years
IMCD India’s innovative formulations bring the Skinification trend to life with cutting-edge solutions across beauty and personal care
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
This Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability
This rating reflects Lupin's leadership in environmental transparency and performance
Subscribe To Our Newsletter & Stay Updated
